Evotec Archives

biotech stock price euronext genmab argenx

News and Trends 25 May 2021

Delayed IPOs and Market Drops Batter Biotech Stocks

Stock markets worldwide have experienced painful instability in the last few months. As a result, the European biotech market has seen stock prices falling and IPOs postponed. The Covid-19 pandemic was a major disruption for stock markets across the globe at the start of 2020. However, markets like Euronext and the tech-focused Nasdaq rallied and […]

May 25, 2021 - 6 minutesmins - By Jonathan Smith

Altheia Science gene therapy autoimmune disease

News and Trends 8 Apr 2020

Evotec Makes Move into Gene Therapy with Takeda Deal

German biotech giant Evotec has moved into gene therapy and partnered with Takeda to develop new therapies in oncology, rare diseases, neuroscience, and gastroenterology. The two companies did not reveal financial details of the collaboration, but did say that it will be a multi-year alliance that adds to Evotec’s existing deal with the big pharma […]

April 8, 2020 - 3 minutesmins - By Helen Albert

In Depth 3 Mar 2020

How Immunotherapy Could Stop and Prevent Type 1 Diabetes

People with type 1 diabetes need lifelong treatments of daily insulin injections to manage their condition that still leave them at risk of long-term complications. Immunotherapy could one day become an insulin-free alternative to stop, prevent, and potentially cure this chronic disease. Type 1 diabetes is an autoimmune disease where the insulin-producing beta cells in […]

March 3, 2020 - 8 minutesmins - By Clara Rodríguez Fernández

How can Proteomics Boost the Discovery of Novel Drugs and Biomarkers?

Proteins, the key players within cells. They carry out enzymatic functions, are involved in signaling cascades, contribute to the structure of cells, and much, much more. Their abundance and intricate functions make the study of the proteome highly complex. However, once decoded, proteins can be highly useful for the discovery and development of novel therapies, […]

October 28, 2019 - 8 minutesmins - By Larissa Warneck-Silvestrin

evotec dna damage repair parp inhibitor cancer

News and Trends 8 Jul 2019

Evotec Spinoff to Develop Cancer Drugs that Block DNA Repair

Breakpoint Therapeutics, a spinoff from the German biotech Evotec, has raised €30M to develop drugs that block DNA repair mechanisms in drug-resistant cancers. Breakpoint Therapeutics aims to develop first-in-class drugs that kill cancer cells by sabotaging their DNA repair machinery. Having taken on a number of Evotec’s drug development programs, Breakpoint aims to have its […]

July 8, 2019 - 2 minutesmins - By Jonathan Smith

evotec tuberculosis treatment gates foundation

More News! 12 Jun 2019

Evotec to Reduce the Burden of Tuberculosis Treatment with €21M Grant

The Bill and Melinda Gates Foundation has granted the German biotech Evotec €21M ($23.8M) to discover drug combinations that can reduce the duration of tuberculosis treatment, which normally takes over six months. Evotec will use the money to test different drug combinations for tuberculosis in the preclinical stage. The partnership will last for five years, […]

June 12, 2019 - 2 minutesmins - By Jonathan Smith

Werner Lanthaler Evotec biotech industry

Interview 17 Apr 2019

What Does the Future Hold for European Biotech? Insights from Evotec’s CEO

As the CEO of Evotec, one of Europe’s largest biotech companies, Werner Lanthaler is in a unique position to look into the future of the biotech industry. At Labiotech Refresh in Vienna, Lanthaler shared his views on where the industry is headed — and how to stay ahead of the game. The last decade has […]

April 17, 2019 - 7 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 May 2018

Celgene Partners With German Biotech to Develop Oncology Treatments

Evotec has entered into a collaboration with Celgene to identify new therapeutics in oncology with a focus on solid tumors. Evotec, based in Hamburg, has received an upfront payment of $65M (€55M) from US-based Celgene, one of the largest biotechs worldwide. The funding will be used to identify potential new cancer treatments with a focus on […]

May 22, 2018 - 2 minutesmins - By Alexander Burik

evotec sanofi infectious disease pipeline

More News! 8 Mar 2018

Evotec Takes Over Sanofi’s Infectious Disease Pipeline

Evotec will be getting over 10 assets, €60M upfront and about 100 scientists from Sanofi’s infectious disease research unit to work on developing new antimicrobials. Evotec has entered exclusive negotiations with Sanofi to accelerate infectious disease R&D through a new innovation platform located near Lyon, France, that will be open to academia, private companies, foundations and government agencies. Sanofi, […]

March 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 28 Dec 2017

Bored Between the Holidays? Watch these Biotech Videos!

Christmas might have passed, but we have more videos for you to watch on a dreary winter day! Here are our highlights from 2017. It’s vacation time! If you’ve worn out the holiday movies, catch up on our biotech ones. It was a busy year, and we produced a lot, thanks to our new Hangouts […]

December 28, 2017 - 4 minutesmins - By Evelyn Warner

Evotec CEO Werner Lanthaler Biotech Innovation Partnerships

Interview 9 Nov 2017

Interview with Europe’s Leader in Biotech Partnerships

I talked with Werner Lanthaler, CEO of Evotec, during Bio Europe 2017 to ask him what the key is to his company’s great success in supporting biotech innovation and establishing strategic partnerships. Evotec started off as a contract research organization in Hamburg back in 1993. Today it has over 2,000 employees worldwide, its own pipeline […]

November 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Oct 2017

Interview: On the Future of iPS Cells and why Partnering is so Important in this Field

In our first part of the interview with Dr David Hallett, Executive Vice President at Evotec, we discussed the uniqueness of Induced Pluripotent Stem Cells (iPS Cells), novel developments occurring in iPS Cell research, and the challenges researchers face. Let us have a short recap of what we have learned so far: iPS Cells were […]

October 16, 2017 - 9 minutesmins - By External Contributor

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us